The prevalence of heart failure is increasing, causing a tremendous burden on health care
systems around the world. Although mortality rate of heart failure has been significantly …

Abstract Corona virus disease-19 (covid-19) is caused by a coronavirus that is also known
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and is generally …

Angiotensin receptor-neprilysin inhibitor (ARNI) and sodium–glucose co-transporter-2
inhibitor (SGLT2i) have shown benefits in diabetic patients with heart failure with reduced …

Pathological sodium-water retention or edema/congestion is a primary cause of heart failure
(HF) decompensation, clinical symptoms, hospitalization, reduced quality of life, and …

In this review, we discuss what is meant by “foundational” therapy for patients with heart
failure and reduced ejection fraction (HFrEF) and the evidence supporting the use of the five …

Background An increasing number of studies have shown that sodium glucose cotransporter
2 (SGLT2) inhibitors, initially used as antidiabetic agents, have cardiovascular (CV) benefits …

Worsening heart failure (WHF) requiring hospitalization represents a vulnerable period for
patients with heart failure. 1, 2 Such individuals, irrespective of the aetiology of heart failure …

Abstract Dapagliflozin [Farxiga®(USA); Forxiga®(EU)], a sodium–glucose cotransporter 2
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …

Patients with type 2 diabetes mellitus (T2D) are at increased risk of cardiovascular (CV)
disease. Sodium glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, are a …

Abstract Background The Heart Failure Collaboratory (HFC) has developed a score
integrating classes and doses of guideline-directed medical therapies prescribed for …